Clinical trials: Multiple Sclerosis Spasticity
Spasticity, Multiple Sclerosis
A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.
The purpose of this study is to evaluate the efficacy, safety and tolerability of Sativex® in subjects diagnosed with MS and spasticity.
- Trial name
- NCT00711646
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 189 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms
To evaluate the safety and tolerability of oral administration of PTL201 for relief of spasticity-related symptoms in 70 MS patients and to evaluate the efficacy of oral administration of PTL201 in relief of spasticity-related…
- Trial name
- NCT03005119
- Testing
- PTL201
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- PhytoTech Therapeutics, Ltd.
Spasticity, Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
To explore the safety and efficacy of IPX056 compared with baclofen tablets for alleviation of symptoms of spasticity associated with multiple sclerosis (MS).
- Trial name
- NCT00914290
- Testing
- IPX056, Baclofen IR
- Where
- 11 sites in United States
- Volunteers
- 23 people
- Sponsor
- Impax Laboratories, LLC
Multiple Sclerosis, Spasticity, Muscle
Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain
This study is based on a 4-week double-blind, randomized, controlled, parallel design investigation to investigate the impact of intermittent negative pressure on spasticity and pain in people with multiple sclerosis (pwMS)…
- Conditions
- Multiple Sclerosis, Spasticity, Muscle, Pain
- Trial name
- NCT05598736
- Testing
- FlowOx 2.0
- Where
- Norway
- Volunteers
- 58 people
- Sponsor
- Otivio AS
Spasticity
Continuous Intrathecal Baclofen Infusion for Chronic Spasticity
The purpose of this clinical investigation is to demonstrate product performance of the Prometra Programmable Pump System in the delivery of intrathecal Lioresal® (baclofen) for the management of severe spasticity.
- Trial name
- CIBI (NCT01051128)
- Testing
- Prometra Programmable Implantable Pump System
- Sponsor
- Flowonix Medical
Spasticity, Multiple Sclerosis
One Year Extension Study To Protocol C2/5/TZ:MS-05
Open label, one year extension study to evaluate the clinical efficacy and safety of 12 mg sublingual tizanidine administered once nightly in MS patients who successfully completed Phase I/II protocol C2/5/TZ:MS-05 at the Tel…
- Trial name
- NCT00464958
- Testing
- sublingual tizanidine 12 mg
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Teva GTC
Spasticity in Participants With Multiple Sclerosis
Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols as adjunctive therapy compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Modified Ashworth Scale…
- Trial name
- RELEASE MSS1 (NCT04657666)
- Testing
- Nabiximols
- Where
- 16 sites in Czechia, Poland
- Volunteers
- 68 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity, Multiple Sclerosis
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
The purpose of this study is to determine whether Sativex® versus Placebo is effective in the relief of symptoms of spasticity in subjects with multiple sclerosis, who have been identified as having a capacity to respond to…
- Trial name
- NCT00681538
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 572 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity, Multiple Sclerosis
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity.
- Trial name
- NCT01743651
- Testing
- arbaclofen, baclofen
- Where
- 48 sites in United States, Russia and 1 more
- Volunteers
- 353 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis, Muscle Spasticity
Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.
This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride…
- Conditions
- Multiple Sclerosis, Muscle Spasticity, Spinal Cord Injury, Stroke
- Trial name
- NCT00047580
- Testing
- tizanidine hydrochloride capsule
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Elan Pharmaceuticals
Multiple Sclerosis
Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the Central Nervous System (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain…
- Trial name
- NCT00053417
- Testing
- 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
- Where
- 25 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).
- Trial name
- NCT01359566
- Testing
- Arbaclofen placarbil 15 mg BID, Arbaclofen placarbil 30 mg BID, Arbaclofen placarbil 45 mg BID
- Where
- 28 sites in United States
- Volunteers
- 228 people
- Sponsor
- XenoPort, Inc.
Multiple Sclerosis
IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
The purpose of this study is to determine the effects, both good and bad, of IPX056 on subjects and their spasticity. This study will also determine the relationship between the amount of IPX056 in blood and the effects on…
- Trial name
- NCT00488839
- Testing
- IPX056 20 mg, IPX056 40 mg, Encapsulated Baclofen 20 mg
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 173 people
- Sponsor
- Impax Laboratories, LLC
Multiple Sclerosis Spasticity
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
- Trial name
- MSS (NCT06782490)
- Testing
- BMS-986368
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- Celgene
Multiple Sclerosis, Spasticity
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
Clinical protocol OS440-3003 is a multicenter, open-label, non-randomized, uncontrolled, dose escalation study to evaluate the safety and tolerability of Arbaclofen Extended Release Tablets over 1 year in Multiple Sclerosis (MS)…
- Trial name
- NCT01844232
- Testing
- arbaclofen
- Where
- 35 sites in United States, Russia and 1 more
- Volunteers
- 150 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis
Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity
Aim of this randomized, double-blind, placebo-controlled, cross-over study is to investigate cannabinoid-induced changes in neurophysiological parameters in a group of 40 patients with secondary or primary progressive Multiple…
- Trial name
- NS-MSS (NCT01538225)
- Testing
- Sativex®
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Almirall, S.A.
Multiple Sclerosis, Spasticity
A Study of the Long-term Safety of Sativex Use
Subjects who had previously received GW-1000-02 in a GW study who opted to continue using it in the long-term were monitored for ongoing tolerability and evidence of clinical benefit.
- Conditions
- Multiple Sclerosis, Spasticity, Pain
- Trial name
- NCT01606137
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 507 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity in People With Multiple Sclerosis
Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis
Phase II a Proof of concept study in Multiple Sclerosis (MS) patients with spasticity.
- Trial name
- NCT02542787
- Testing
- VSN16R
- Where
- 4 sites in United Kingdom
- Volunteers
- 160 people
- Sponsor
- Canbex Therapeutics Ltd
Spasticity, Multiple Sclerosis
Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study is to evaluate the maintenance of effect after long-term treatment with Sativex® in subjects with symptoms of spasticity due to Multiple Sclerosis (MS) who have been receiving long-term benefit from…
- Trial name
- NCT00702468
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Jazz Pharmaceuticals
Muscle Spasticity, Hypertonia, Muscle
Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals
To assess the safety and tolerability of single and multiple doses of MTR-601 in normal healthy volunteers under fed and fasted conditions. To evaluate the plasma and urine pharmacokinetics (PK) of MTR-601.
- Conditions
- Muscle Spasticity, Hypertonia, Muscle, Cerebral Palsy, Multiple Sclerosis
- Trial name
- NCT06117020
- Testing
- MTR-601
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Motric Bio